Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (61)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wendel, K. A.
Right arrow Articles by Sterling, T. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wendel, K. A.
Right arrow Articles by Sterling, T. R.
(Chest. 2001;120:193-197.)
© 2001 American College of Chest Physicians

Paradoxical Worsening of Tuberculosis in HIV-Infected Persons*

Karen A. Wendel, MD; Karla S. Alwood, CRNP; Regina Gachuhi, MS; Richard E. Chaisson, MD; William R. Bishai, MD, PhD and Timothy R. Sterling, MD

* From the Division of Infectious Diseases (Drs. Wendel, Chaisson, Sterling, and Ms. Alwood), Johns Hopkins University School of Medicine; Baltimore City Health Department Eastern Chest Clinic (Drs. Gachuhi and Sterling); and Department of International Health (Dr. Bishai), Johns Hopkins University School of Public Health, Baltimore, MD.

Correspondence to: Karen A. Wendel, MD, Division of Infectious Diseases, 1830 E. Monument St, Room 401, Baltimore, MD 21287; e-mail: kwwendel{at}mail.jhmi.edu

Objective: To determine the incidence of paradoxical worsening of tuberculosis (TB) in HIV-infected persons.

Design: Observational cohort study.

Setting: Public, urban TB clinic.

Patients: HIV-infected persons treated for TB between January 1, 1996, and December 31, 1999, and followed through June 30, 2000.

Intervention: Patients received standard anti-TB therapy. Antiretroviral therapy was provided by primary medical providers. Patients receiving antiretroviral therapy were given nucleoside reverse transcriptase inhibitors alone or highly active antiretroviral therapy (HAART; nucleoside reverse transcriptase inhibitors in combination with a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor).

Main outcome measure: Paradoxical worsening of TB.

Results: There were 82 TB cases in 76 patients. Paradoxical worsening was identified in 6 of 82 cases (7%; 95% confidence interval, 3 to 15%). Paradoxical worsening occurred in 3 of 28 cases (11%) in patients receiving HAART and in 3 of 44 cases (7%) in patients not receiving antiretroviral therapy (p = 0.67). Cases complicated by paradoxical worsening were more likely to have both pulmonary and extrapulmonary disease at initial diagnosis than cases without paradoxical worsening (83% vs 24%; p = 0.006). TB relapse occurred in 2 of 6 cases (33%) in patients with paradoxical worsening and in 4 of 76 cases (5%) in patients without paradoxical worsening (p = 0.06).

Conclusions: Paradoxical worsening of TB occurred less frequently than in previous reports and was not associated with HAART. Paradoxical worsening also appeared to be associated with an increased risk of TB relapse. Further studies are warranted to better characterize the risk factors for paradoxical worsening and the appropriate duration of anti-TB therapy in patients in whom it occurs.

Key Words: antiretroviral therapy • HIV infection • lung • lymphadenopathy • paradoxical worsening • tuberculosis




This article has been cited by other articles:


Home page
Sex. Transm. Infect.Home page
R F Miller, S S Dave, J W Tang, P J Shaw, H R Jager, and E G L Wilkins
Progressive neuropsychiatric problems following institution of highly active antiretroviral therapy
Sex. Transm. Inf., August 1, 2005; 81(4): 351 - 357.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
R A M Breen, C J Smith, H Bettinson, S Dart, B Bannister, M A Johnson, and M C I Lipman
Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection
Thorax, August 1, 2004; 59(8): 704 - 707.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis
Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 603 - 662.
[Full Text] [PDF]


Home page
Eur Respir JHome page
M.D. Iseman
Tuberculosis therapy: past, present and future
Eur. Respir. J., July 1, 2002; 20(36_suppl): 87S - 94s.
[Abstract] [Full Text] [PDF]


Home page
AIDS Clin CareHome page
Tuberculosis and HIV
AIDS Clinical Care, February 1, 2002; 2002(201): 6 - 6.
[Full Text]

eLetters:

Read all eLetters

Sequence of HAART/anti-mycobacterial therapy and nadir CD4 count might be important for Tb flare up
Furrer Hansjakob
Chest Online, 28 Aug 2001 [Full text]



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American College of Chest Physicians.